Total Payments
$1.4M
2024 Payments
$234,861
Companies
52
Transactions
1,335
Medicare Patients
17,824
Medicare Billing
$2.3M
Payment Breakdown by Category
Other$1.0M (72.1%)
Consulting$204,587 (14.4%)
Travel$161,701 (11.4%)
Food & Beverage$19,736 (1.4%)
Research$9,978 (0.7%)
Education$259.69 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.0M | 407 | 71.0% |
| Consulting Fee | $204,587 | 81 | 14.4% |
| Travel and Lodging | $161,701 | 308 | 11.4% |
| Food and Beverage | $19,736 | 524 | 1.4% |
| Honoraria | $12,531 | 6 | 0.9% |
| Unspecified | $9,978 | 2 | 0.7% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $3,000 | 1 | 0.2% |
| Education | $259.69 | 6 | 0.0% |
Payments by Type
General
$1.4M
1,333 transactions
Research
$9,978
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | $346,297 | 293 | $0 (2024) |
| Janssen Biotech, Inc. | $228,513 | 220 | $0 (2024) |
| Astellas Pharma US Inc | $204,736 | 194 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $178,193 | 98 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $115,455 | 96 | $0 (2024) |
| Merck Sharp & Dohme LLC | $87,206 | 48 | $0 (2024) |
| Sumitomo Pharma America, Inc. | $59,239 | 28 | $0 (2024) |
| PFIZER INC. | $52,260 | 114 | $0 (2024) |
| Myovant Sciences Inc. | $40,057 | 33 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $22,688 | 11 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $234,861 | 166 | Astellas Pharma US Inc ($51,117) |
| 2023 | $259,042 | 161 | Bayer Healthcare Pharmaceuticals Inc. ($45,677) |
| 2022 | $193,089 | 129 | Bayer HealthCare Pharmaceuticals Inc. ($57,036) |
| 2021 | $94,266 | 121 | Janssen Biotech, Inc. ($23,659) |
| 2020 | $117,945 | 106 | Janssen Biotech, Inc. ($45,570) |
| 2019 | $117,892 | 142 | Janssen Biotech, Inc. ($49,420) |
| 2018 | $176,067 | 212 | Janssen Scientific Affairs, LLC ($117,367) |
| 2017 | $227,272 | 298 | Bayer HealthCare Pharmaceuticals Inc. ($103,226) |
All Payment Transactions
1,335 individual payment records from CMS Open Payments — Page 1 of 54
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Education | In-kind items and services | $40.75 | General |
| Category: Oncology | ||||||
| 12/14/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $16.20 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Consulting Fee | Cash or cash equivalent | $670.00 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Janssen Global Services, LLC | — | Consulting Fee | Cash or cash equivalent | $1,665.00 | General |
| 12/05/2024 | Janssen Global Services, LLC | — | Food and Beverage | In-kind items and services | $140.20 | General |
| 12/05/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $75.67 | General |
| Category: HORMONE THERAPY | ||||||
| 12/04/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,550.00 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,580.00 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 12/04/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Travel and Lodging | Cash or cash equivalent | $379.88 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Travel and Lodging | Cash or cash equivalent | $318.38 | General |
| Category: Oncology | ||||||
| 12/03/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $3.29 | General |
| Category: ONCOLOGY | ||||||
| 11/22/2024 | UROGEN PHARMA, INC. | — | Consulting Fee | Cash or cash equivalent | $1,562.50 | General |
| 11/22/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $1,012.50 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,575.00 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $128.05 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,580.00 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 11/12/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $2,025.00 | General |
| Category: Oncology | ||||||
| 11/08/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,400.00 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,815.00 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | Cash or cash equivalent | $25.00 | General |
| Category: ONCOLOGY | ||||||
| 11/01/2024 | Tolmar, Inc. | ELIGARD (Drug) | Food and Beverage | Cash or cash equivalent | $20.30 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $550.00 | General |
| Category: Oncology | ||||||
| 10/30/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,580.00 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 10/25/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $95.90 | General |
| Category: Oncology | ||||||
| 10/25/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $81.71 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| APA-OUT-044 PHANTOM project Dr. Gordon Brown | Janssen Scientific Affairs, LLC | $7,000 | 1 |
| APA-OUT-044_PHANTOM project Dr. Gordon Brown | Janssen Scientific Affairs, LLC | $2,978 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 41 | 4,030 | 12,090 | $2.5M | $518,576 |
| 2022 | 42 | 4,987 | 12,906 | $1.9M | $485,753 |
| 2021 | 33 | 4,511 | 13,074 | $2.0M | $509,099 |
| 2020 | 43 | 4,296 | 41,955 | $3.4M | $826,996 |
Total Patients
17,824
Total Services
80,025
Medicare Billing
$2.3M
Procedure Codes
159
All Medicare Procedures & Services
159 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 969 | 1,775 | $333,700 | $114,793 | 34.4% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 83 | 741 | $510,459 | $98,680 | 19.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 539 | 931 | $255,094 | $90,283 | 35.4% |
| 55874 | Injection of biodegradable material next to prostate | Office | 2023 | 16 | 16 | $356,976 | $41,468 | 11.6% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Office | 2023 | 112 | 160 | $142,400 | $31,261 | 22.0% |
| J9155 | Injection, degarelix, 1 mg | Office | 2023 | 23 | 5,520 | $38,640 | $17,803 | 46.1% |
| 76872 | Ultrasound scan of pelvic region through rectum | Office | 2023 | 113 | 125 | $42,500 | $14,672 | 34.5% |
| 55700 | Biopsy of prostate gland | Office | 2023 | 67 | 68 | $98,124 | $12,710 | 13.0% |
| A4648 | Tissue marker, implantable, any type, each | Office | 2023 | 22 | 22 | $75,240 | $11,603 | 15.4% |
| 50543 | Partial removal of kidney using an endoscope | Facility | 2023 | 12 | 12 | $104,220 | $10,678 | 10.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 92 | 92 | $25,208 | $7,514 | 29.8% |
| 52240 | Destruction and/or removal of large growth of bladder using an endoscope | Facility | 2023 | 17 | 19 | $84,436 | $5,893 | 7.0% |
| 52234 | Destruction and/or removal of growth of bladder and urethra using an endoscope, 0.5-2.0 cm | Office | 2023 | 19 | 26 | $49,530 | $5,196 | 10.5% |
| 52310 | Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | Office | 2023 | 17 | 19 | $26,600 | $5,105 | 19.2% |
| 51728 | Complex measurement of pressure of urine flow in bladder with voiding pressure studies | Office | 2023 | 15 | 15 | $26,055 | $4,808 | 18.5% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 92 | 160 | $19,360 | $4,350 | 22.5% |
| 52235 | Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | Facility | 2023 | 17 | 19 | $60,325 | $4,152 | 6.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 27 | 27 | $11,124 | $3,371 | 30.3% |
| 52332 | Insertion of stent in ureter using an endoscope | Facility | 2023 | 27 | 33 | $82,500 | $3,159 | 3.8% |
| 51798 | Ultrasound measurement of bladder capacity after voiding | Office | 2023 | 257 | 338 | $38,870 | $2,904 | 7.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 18 | 19 | $9,443 | $2,746 | 29.1% |
| 51797 | Insertion of device into abdomen with pressure and urine flow rate study | Office | 2023 | 15 | 15 | $19,125 | $2,558 | 13.4% |
| 76775 | Limited ultrasound scan behind abdominal cavity | Office | 2023 | 43 | 51 | $10,251 | $2,313 | 22.6% |
| 55876 | Placement of device in prostate for radiation therapy | Office | 2023 | 24 | 24 | $18,384 | $2,284 | 12.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 20 | 21 | $7,056 | $2,277 | 32.3% |
About Dr. Gordon Brown, DO
Dr. Gordon Brown, DO is a Urology healthcare provider based in Cherry Hill, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1124192489.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gordon Brown, DO has received a total of $1.4M in payments from pharmaceutical and medical device companies, with $234,861 received in 2024. These payments were reported across 1,335 transactions from 52 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.0M).
As a Medicare-enrolled provider, Brown has provided services to 17,824 Medicare beneficiaries, totaling 80,025 services with total Medicare billing of $2.3M. Data is available for 4 years (2020–2023), covering 159 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Other Specialties Urology
- Location Cherry Hill, NJ
- Active Since 11/20/2006
- Last Updated 11/21/2025
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1124192489
Products in Payments
- Xofigo (Drug) $195,792
- ERLEADA (Drug) $177,154
- Erleada (Drug) $162,662
- Nubeqa (Drug) $150,505
- Xtandi (Drug) $144,678
- LYNPARZA (Drug) $110,790
- ORGOVYX (Drug) $101,818
- KEYTRUDA (Biological) $75,821
- XTANDI (Drug) $63,719
- DARZALEX (Biological) $30,673
- PLUVICTO (Drug) $22,688
- TALZENNA (Drug) $17,927
- PYLARIFY (Drug) $14,231
- ELIGARD (Drug) $11,979
- PROVENGE (Drug) $8,238
- JEVTANA (Drug) $7,764
- Rubraca (Drug) $4,200
- FOUNDATIONACT (Device) $4,056
- ADSTILADRIN (Drug) $3,756
- Biograph Horizon-3R (Device) $3,600
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Urology Doctors in Cherry Hill
Louis Keeler, Md, MD
Urology — Payments: $33,076
Urology $33,076
Dr. Masaya Jimbo, Md, Phd, MD, PHD
Urology — Payments: $8,325
Urology $8,325
Andre Filipe Miranda, Md, MD
Urology — Payments: $7,497
Urology $7,497
Randy Ackerman, Md, MD
Urology — Payments: $5,862
Urology $5,862
Paul Thur, M.d, M.D
Urology — Payments: $5,436
Urology $5,436
Shih-Han Chow, M.d, M.D
Urology — Payments: $3,994
Urology $3,994